Introduction
The disclosed subject matter relates to a method for diagnosing cancer, degenerative diseases, infectious diseases, and aging in an individual. In certain embodiments according to the disclosed subject matter, the method comprises (a) obtaining a biological sample from the individual; (b) isolating multiple extracellular vesicles from the biological sample; (c) determining the expression level of specific biomarkers within the multiple extracellular vesicles; and (d) diagnosing or predicting the presence of the cancer, degenerative disease, infectious disease, or aging based on the expression level of the biomarker determined in step (c).
Features / strengths
1. This patent has been deployed in Taiwan/Japan and obtained a patent certificate.
2. Different extracellular and in vivo miRNA profiles between old and young can be used as monitoring indicators. The biological specimen is blood, urine, cerebrospinal fluid, pleural effusion, malignant ascites, breast milk, amniotic fluid, birth canal fluid, gastrointestinal tract fluid, bronchoalveolar lavage fluid or saliva.
3. The extracellular body (EV) of the elderly has low growth hormone and high inflammatory substances.
4. When diagnosing the degenerative disease, the biological specimen is the blood or urine; and the biomarker is selected from EGF, chemotactic protein, IFN-α, L1CAM, α-synuclein, IFN-γ, A group consisting of GRO, IL-10, MCP-3, exoDNA and combinations thereof, wherein when compared with the control sample, EGF, chemotactic proteins, IFN-α, IFN-γ, GRO, When the expression level of IL-10 or MCP-3 is low; and/or when the expression amount of L1CAM, α-synuclein or exoDNA in the biological specimen is high compared with the control sample.
5. If the request is for diagnosing the cancer, the biological sample is the urine; and the biomarker is selected from the group consisting of E-cadherin, L1CAM, α-synuclein, S100A8, Muc5AC and combinations thereof A group in which a higher expression of the biomarker in the biological specimen indicates that the individual has the cancer when compared to the control sample. When compared with the control sample, E-cadherin, ICOS-L, Muc5AC, dermin, CGREF1, cochlin protein, AREG, LRG, guanine deaminase, S100A8, NGAL, hsa- The expression amount of miR-10a-5p or hsa-miR-182-5p.
Specification in detail
研發中
Seek of partners for business cooperation
